Jamison Private Wealth Management Inc. Cuts Stock Holdings in GSK plc (NYSE:GSK)

Jamison Private Wealth Management Inc. reduced its position in GSK plc (NYSE:GSK) by 4.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,038 shares of the pharmaceutical company’s stock after selling 811 shares during the period. Jamison Private Wealth Management Inc.’s holdings in GSK were worth $576,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in GSK. Eastern Bank purchased a new stake in shares of GSK during the 3rd quarter worth about $26,000. Sunbelt Securities Inc. boosted its position in GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after purchasing an additional 302 shares in the last quarter. Concord Wealth Partners boosted its position in GSK by 231.8% during the third quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock worth $32,000 after purchasing an additional 547 shares in the last quarter. ST Germain D J Co. Inc. increased its position in shares of GSK by 195.5% in the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 522 shares in the last quarter. Finally, Fortitude Family Office LLC purchased a new stake in shares of GSK in the third quarter valued at approximately $42,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Trading Up 0.7 %

GSK opened at $34.29 on Friday. The firm has a market capitalization of $71.06 billion, a price-to-earnings ratio of 22.26, a price-to-earnings-growth ratio of 1.31 and a beta of 0.63. The company’s 50 day simple moving average is $33.91 and its two-hundred day simple moving average is $37.81. GSK plc has a 1-year low of $31.72 and a 1-year high of $45.92. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, January 9th. Investors of record on Friday, November 15th were given a dividend of $0.3928 per share. This is an increase from GSK’s previous quarterly dividend of $0.38. The ex-dividend date of this dividend was Friday, November 15th. This represents a $1.57 dividend on an annualized basis and a yield of 4.58%. GSK’s dividend payout ratio (DPR) is presently 96.10%.

Wall Street Analysts Forecast Growth

GSK has been the topic of a number of research analyst reports. Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and dropped their target price for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. StockNews.com downgraded shares of GSK from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 21st. Finally, Deutsche Bank Aktiengesellschaft cut GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Six analysts have rated the stock with a hold rating, one has given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.